Similis Bio Collaboration with Novel351k to Develop Multiple Biosimilar Programs for Cancer and Autoimmune Diseases
Shots:
- The companies collaborated to co-develop 3 biosimilar programs across hard-to-treat diseases. The collaboration combines Similis’ broad CMC expertise with Novel351k’s innovative clinical approach to advance the delivery of life-saving therapies to eligible patients at lower cost
- Similis will lead the cell line development, analytics, process development & cGMP production, leading to PK/PD trials. Novel351k will use its experience with regulatory and clinical strategies to advance the program's development toward commercialization
- The therapies developed under the collaboration have a $15B+ annual market value. Under the co-development agreement, Similis Bio & Novel351k is expected to be valued at $100M incl. development milestones and royalties for ~10yrs.
Ref: Businesswire | Image: Similis Bio
Related News:- Similis Bio Entered into a Development and License Agreement with Blau Farmaceutica to Co-Develop Four Biosimilar Programs
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
